版本:
中国

BRIEF-Ocera initiates phase 1 clinical study of OCR-002

Sept 19 Ocera Therapeutics :

* Initiates phase 1 clinical study of orally available OCR-002 in patients with cirrhosis for the prevention of hepatic encephalopathy

* Phase 2B stop-HE enrollment surpasses 205 patients; on track to complete in Q4 2016

* Intend to initiate a phase 2 development program for orally-available OCR-002 upon satisfactory results from both parts of phase 1 trial Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐